-
Arrowhead Pharmaceuticals Reports Successful Topline Results for Plozasiran from the Pivotal Phase 3 PALISADE Study in Patients with Familial Chylomicronemia Syndrome
03 Jun 2024 11:40 GMT
… most. This moment represents validation of all the hard work … arrowheadpharma.com.
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals develops medicines that treat … events or circumstances.
Source: Arrowhead Pharmaceuticals, Inc.
View source version …
-
Bispecific And Trispecific Antibodies Market To Observe Stupendous Growth By 2035, Predicts Delveinsight Key Companies - Akeso, Summit Therapeutics, Zymeworks, Beigene, Jazz Pharmaceuticals, Merus, Roche
03 Jun 2024 10:24 GMT
… robust preclinical and clinical validation . Overcoming these challenges … Biopharmaceuticals, Sichuan Baili Pharmaceutical, Regeneron Pharmaceuticals, Boehringer Ingelheim, among … Seagen Inc., Ascletis Pharma Inc., Secarna Pharmaceuticals GmbH & Co …
-
Mayo Clinic Validation of the AUA Risk Groups for Localized Renal Cell Carcinoma.
03 Jun 2024 08:41 GMT
The AUA guidelines introduced a new risk group stratification system based primarily on tumor stage and grade to guide surveillance for patients treated surgically for localized renal cell carcinoma (RCC). We sought to evaluate the predictive ability of …
-
Development and validation of an ELISA to measure regenerating island-derived protein 3E in canine blood.
03 Jun 2024 06:28 GMT
Regenerating island-derived proteins (REG) are upregulated in people with sepsis, pancreatitis, and gastrointestinal diseases. One member of the REG family, namely REG3E, was recently identified in pancreatic tissue and plasma of dogs, with high expression …
-
Enhanced Prognostic Factors for Disease-Free Survival in Penile Squamous Cell Carcinoma: Insights From Songklanagarind Hospital.
03 Jun 2024 15:25 GMT
This study aimed to investigate disease-free survival (DFS) outcomes and associated prognostic factors among surgically treated penile cancer patients at Songklanagarind Hospital, Thailand, over a 20-year period.
A retrospective analysis was conducted on …
-
Paediatric medicines: applications and procedures
03 Jun 2024 14:38 GMT
As of 4 June 2024, applicants should use the IRIS platform for the following types of procedure:
Initial paediatric investigation plan (PIP)
Modification of an agreed PIP
Product-specific waiver
Compliance check
Annual report on paediatric deferred …
-
NeoImmuneTech's New Data at ASCO 2024 Highlights Enhanced Benefits of Combining NT-I7 with Checkpoint Inhibitors (CPI) in Immuno-Oncology
03 Jun 2024 12:23 GMT
Results from study NIT-110 with NT-I7 and CPI combination treatment show median overall survival (mOS) improvements over standard of care treatment in pancreatic cancer and MSS colorectal cancer
Correlative analysis identified potentially predictive …
-
IDEAYA Announces Results for Darovasertib Phase 2 IST in Neoadjuvant Uveal Melanoma at ASCO and Clinical Update for Phase 2 Company-Sponsored Neoadjuvant Study
03 Jun 2024 12:54 GMT
75% eye preservation rate (9 of 12 enucleation patients)
~67% (8 of 12 enucleation patients) observed greater than 30% tumor shrinkage and median tumor shrinkage of 47% by volume change after 6 months
Company-sponsored Phase 2 Neoadjuvant UM: Over 40 …
-
Knowledge and practices regarding prostate cancer screening in Spanish men: The importance of personal and clinical characteristics (PROSHADE study).
03 Jun 2024 13:23 GMT
Patients' decisions on prostate cancer (PCa) opportunistic screening may vary. This study aimed to assess how demographic and health-related characteristics may influence knowledge and decisions regarding PCa screening.
A cross-sectional survey was …
-
Discovery and Validation of a 15-Gene Prognostic Signature for Clear Cell Renal Cell Carcinoma.
31 May 2024 11:20 GMT
Develop and validate gene expression-based biomarker associated with recurrent disease to facilitate risk stratification of clear cell renal cell carcinoma (ccRCC).
We retrospectively identified 110 patients who underwent radical nephrectomy for ccRCC ( …